Sign In
Buy ALRN
$2.11
+0 (+0%)
At Close: Apr 09, 2025
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
11:30am, Friday, 10'th Jan 2025
Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets Company sha
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
04:15pm, Thursday, 14'th Nov 2024
Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent eff
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a b
Agreement marks first of its kind for Advancium, a public charity launched by Deerfield Management and the Deerfield Foundation Advancium will evaluate ALRN-6924 as a potential therapy for retinoblas
First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the
Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect
Aileron Therapeutics to Present at the 8th Annual IPF Summit
04:05pm, Monday, 19'th Aug 2024
AUSTIN, Texas , Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address signi
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
06:05pm, Wednesday, 14'th Aug 2024
Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends o
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
08:00am, Tuesday, 30'th Jul 2024
AUSTIN, Texas , July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address signi
Aileron Therapeutics to be Included in the Russell Microcap® Index
08:00am, Monday, 01'st Jul 2024
AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
05:13pm, Wednesday, 15'th May 2024
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
10:36am, Tuesday, 07'th May 2024
The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
04:05pm, Monday, 06'th May 2024
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
04:05pm, Friday, 03'rd May 2024
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes in
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes in
